// February 08, 2019
Our Legacy of Championing Access to Medicines
Access to medicines is a complicated topic.
Access to medicines is a complicated topic.
By the year 2020, biopharmaceuticals are estimated to account for 50% of the most successful phar
Highly complex biologics such as proteins, monoclonal antibodies, and cell and gene therapies inc
In 2015 and 2016, USP launched a series of “roundtable” events designed to engage industry in dis